The European Medicines Agency has recommended that eight new medicines be awarded pan-EU marketing authorization, including Zolgensma, AveXis/Novartis’s one-off gene replacement therapy for treating spinal muscular atrophy in babies and young children.
Zolgensma and Seven Other Products Get CHMP Thumbs Up
Zolgensma should receive a conditional approval, says the European Medicines Agency’s drug evaluation committee, the CHMP.
